{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:09:52Z","timestamp":1794492592204,"version":"4.9.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T00:00:00Z","timestamp":1539216000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13045-018-0670-9","type":"journal-article","created":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T20:52:08Z","timestamp":1539204728000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)"],"prefix":"10.1186","volume":"11","author":[{"given":"Xu","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Briaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Becette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Benoist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anais","family":"Boulai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Chemlali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Schnitzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Baulande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Ange","family":"Mouret-Reynier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence Venat","family":"Bouvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaut","family":"De La Motte Rouge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Lemonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Lerebours","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3377-4937","authenticated-orcid":false,"given":"C\u00e9line","family":"Callens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,11]]},"reference":[{"key":"670_CR1","doi-asserted-by":"crossref","unstructured":"Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106.","DOI":"10.1093\/jnci\/dju055"},{"key":"670_CR2","doi-asserted-by":"crossref","unstructured":"Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists\u2019 Group, Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45\u201353.","DOI":"10.1016\/S1470-2045(07)70385-6"},{"key":"670_CR3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/978-3-319-22909-6_5","volume":"882","author":"CX Ma","year":"2016","unstructured":"Ma CX, Bose R, Ellis MJ. Prognostic and predictive biomarkers of endocrine responsiveness for estrogen receptor positive breast Cancer. Adv Exp Med Biol. 2016;882:125\u201354.","journal-title":"Adv Exp Med Biol"},{"key":"670_CR4","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1200\/JCO.2008.16.8849","volume":"27","author":"WR Miller","year":"2009","unstructured":"Miller WR, Larionov A, Renshaw L, Anderson TJ, Walker JR, Krause A, et al. Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. J Clin Oncol. 2009;27:1382\u20137.","journal-title":"J Clin Oncol"},{"key":"670_CR5","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s10549-010-0887-y","volume":"121","author":"M Mello-Grand","year":"2010","unstructured":"Mello-Grand M, Singh V, Ghimenti C, Scatolini M, Regolo L, Grosso E, et al. Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer. Breast Cancer Res Treat. 2010;121:399\u2013411.","journal-title":"Breast Cancer Res Treat"},{"key":"670_CR6","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s10549-008-9897-4","volume":"112","author":"DM Harvell","year":"2008","unstructured":"Harvell DM, Spoelstra NS, Singh M, McManaman JL, Finlayson C, Phang T, et al. Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance. Breast Cancer Res Treat. 2008;112:475\u201388.","journal-title":"Breast Cancer Res Treat"},{"key":"670_CR7","doi-asserted-by":"publisher","first-page":"e87415","DOI":"10.1371\/journal.pone.0087415","volume":"9","author":"S Knudsen","year":"2014","unstructured":"Knudsen S, Jensen T, Hansen A, Mazin W, Lindemann J, Kuter I, et al. Development and validation of a gene expression score that predicts response to fulvestrant in breast cancer patients. PLoS One. 2014;9:e87415.","journal-title":"PLoS One"},{"key":"670_CR8","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12885-016-2270-9","volume":"16","author":"T Ueno","year":"2016","unstructured":"Ueno T, Saji S, Sugimoto M, Masuda N, Kuroi K, Sato N, et al. Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy. BMC Cancer. 2016;16:230.","journal-title":"BMC Cancer"},{"key":"670_CR9","doi-asserted-by":"publisher","first-page":"12498","DOI":"10.1038\/ncomms12498","volume":"7","author":"CA Miller","year":"2016","unstructured":"Miller CA, Gindin Y, Lu C, Griffith OL, Griffith M, Shen D, et al. Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers. Nat Commun. 2016;7:12498.","journal-title":"Nat Commun"},{"key":"670_CR10","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1200\/JCO.2014.57.8963","volume":"33","author":"AK Turnbull","year":"2015","unstructured":"Turnbull AK, Arthur LM, Renshaw L, Larionov AA, Kay C, Dunbier AK, et al. Accurate prediction and validation of response to endocrine therapy in breast Cancer. J Clin Oncol. 2015;33:2270\u20138.","journal-title":"J Clin Oncol"},{"key":"670_CR11","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1002\/cncr.30143","volume":"122","author":"F Lerebours","year":"2016","unstructured":"Lerebours F, Rivera S, Mouret-Reynier MA, Alran S, Venat-Bouvet L, Kerbrat P, et al. Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: results of the UNICANCER CARMINA 02 French trial (UCBG 0609). Cancer. 2016;122:3032\u201340.","journal-title":"Cancer"},{"key":"670_CR12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014. Ann Oncol. 2015;26:259\u201371.","journal-title":"Ann Oncol"},{"key":"670_CR13","doi-asserted-by":"publisher","first-page":"R36","DOI":"10.1186\/gb-2013-14-4-r36","volume":"14","author":"D Kim","year":"2013","unstructured":"Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14:R36.","journal-title":"Genome Biol"},{"key":"670_CR14","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nbt.1621","volume":"28","author":"C Trapnell","year":"2010","unstructured":"Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010;28:511\u20135.","journal-title":"Nat Biotechnol"},{"key":"670_CR15","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.","journal-title":"Nucleic Acids Res"},{"key":"670_CR16","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","volume":"30","author":"A Kramer","year":"2014","unstructured":"Kramer A, Green J, Pollard J Jr, Tugendreich S. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics. 2014;30:523\u201330.","journal-title":"Bioinformatics"},{"key":"670_CR17","doi-asserted-by":"publisher","first-page":"e0190619","DOI":"10.1371\/journal.pone.0190619","volume":"13","author":"S Vacher","year":"2018","unstructured":"Vacher S, Castagnet P, Chemlali W, Lallemand F, Meseure D, Pocard M, et al. High AHR expression in breast tumors correlates with expression of genes from several signaling pathways namely inflammation and endogenous tryptophan metabolism. PLoS One. 2018;13:e0190619.","journal-title":"PLoS One"},{"key":"670_CR18","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1373\/clinchem.2017.272518","volume":"64","author":"C Decraene","year":"2018","unstructured":"Decraene C, Silveira AB, Bidard FC, Vallee A, Michel M, Melaabi S, et al. Multiple hotspot mutations scanning by single droplet digital PCR. Clin Chem. 2018;64:317\u201328.","journal-title":"Clin Chem"},{"key":"670_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Cancer Genome Atlas N","year":"2012","unstructured":"Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61\u201370.","journal-title":"Nature"},{"key":"670_CR20","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1158\/1078-0432.CCR-13-1378","volume":"20","author":"N Patani","year":"2014","unstructured":"Patani N, Dunbier AK, Anderson H, Ghazoui Z, Ribas R, Anderson E, et al. Differences in the transcriptional response to fulvestrant and estrogen deprivation in ER-positive breast cancer. Clin Cancer Res. 2014;20:3962\u201373.","journal-title":"Clin Cancer Res"},{"key":"670_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.gde.2006.12.002","volume":"17","author":"BD Spiegelberg","year":"2007","unstructured":"Spiegelberg BD, Hamm HE. Roles of G-protein-coupled receptor signaling in cancer biology and gene transcription. Curr Opin Gnet Dev. 2007;17:40\u20134.","journal-title":"Curr Opin Gnet Dev"},{"key":"670_CR22","doi-asserted-by":"publisher","first-page":"934","DOI":"10.3892\/ijo.2016.3590","volume":"49","author":"HJ Park","year":"2016","unstructured":"Park HJ, Kim MK, Choi KS, Jeong JW, Bae SK, Kim HJ, et al. Neuromedin B receptor antagonism inhibits migration, invasion, and epithelial-mesenchymal transition of breast cancer cells. Int J Oncol. 2016;49:934\u201342.","journal-title":"Int J Oncol"},{"key":"670_CR23","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2967\/jnumed.115.160739","volume":"56","author":"SU Dalm","year":"2015","unstructured":"Dalm SU, Sieuwerts AM, Look MP, Melis M, van Deurzen CH, Foekens JA, et al. Clinical relevance of targeting the gastrin-releasing peptide receptor, somatostatin receptor 2, or chemokine C-X-C motif receptor 4 in breast Cancer for imaging and therapy. J Nucl Med. 2015;56:1487\u201393.","journal-title":"J Nucl Med"},{"key":"670_CR24","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.2967\/jnumed.116.188011","volume":"58","author":"C Morgat","year":"2017","unstructured":"Morgat C, MacGrogan G, Brouste V, Velasco V, Sevenet N, Bonnefoi H, et al. Expression of gastrin-releasing peptide receptor in breast cancer and its association with pathologic, biologic, and clinical parameters: a study of 1,432 primary tumors. J Nucl Med. 2017;58:1401\u20137.","journal-title":"J Nucl Med"},{"key":"670_CR25","doi-asserted-by":"publisher","first-page":"e0157453","DOI":"10.1371\/journal.pone.0157453","volume":"11","author":"K Leithner","year":"2016","unstructured":"Leithner K, Hirschmugl B, Li Y, Tang B, Papp R, Nagaraj C, et al. TASK-1 regulates apoptosis and proliferation in a subset of non-small cell lung cancers. PLoS One. 2016;11:e0157453.","journal-title":"PLoS One"},{"key":"670_CR26","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1093\/annonc\/mdu112","volume":"25","author":"S Loi","year":"2014","unstructured":"Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014;25:1544\u201350.","journal-title":"Ann Oncol"},{"key":"670_CR27","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1200\/JCO.2013.55.0491","volume":"32","author":"S Adams","year":"2014","unstructured":"Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32:2959\u201366.","journal-title":"J Clin Oncol"},{"key":"670_CR28","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1200\/JCO.2014.58.1967","volume":"33","author":"C Denkert","year":"2015","unstructured":"Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33:983\u201391.","journal-title":"J Clin Oncol"},{"key":"670_CR29","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","volume":"31","author":"S Loi","year":"2013","unstructured":"Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31:860\u20137.","journal-title":"J Clin Oncol"},{"key":"670_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ctrv.2016.03.011","volume":"46","author":"MV Dieci","year":"2016","unstructured":"Dieci MV, Griguolo G, Miglietta F, Guarneri V. The immune system and hormone-receptor positive breast cancer: is it really a dead end? Cancer Treat Rev. 2016;46:9\u201319.","journal-title":"Cancer Treat Rev"},{"key":"670_CR31","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-12-1000","volume":"19","author":"AK Dunbier","year":"2013","unstructured":"Dunbier AK, Ghazoui Z, Anderson H, Salter J, Nerurkar A, Osin P, et al. Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance. Clin Cancer Res. 2013;19:2775\u201386.","journal-title":"Clin Cancer Res"},{"key":"670_CR32","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3389\/fendo.2017.00293","volume":"8","author":"C Blucher","year":"2017","unstructured":"Blucher C, Stadler SC. Obesity and breast cancer: current insights on the role of fatty acids and lipid metabolism in promoting breast Cancer growth and progression. Front Endocrinol (Lausanne). 2017;8:293.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"670_CR33","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S1097-2765(00)80211-7","volume":"4","author":"ED Rosen","year":"1999","unstructured":"Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell. 1999;4:611\u20137.","journal-title":"Mol Cell"},{"key":"670_CR34","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s10549-009-0575-y","volume":"119","author":"MJ Ellis","year":"2010","unstructured":"Ellis MJ, Lin L, Crowder R, Tao Y, Hoog J, Snider J, et al. Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res Treat. 2010;119:379\u201390.","journal-title":"Breast Cancer Res Treat"},{"key":"670_CR35","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1200\/JCO.2008.18.8391","volume":"27","author":"J Baselga","year":"2009","unstructured":"Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009;27:2630\u20137.","journal-title":"J Clin Oncol"},{"key":"670_CR36","doi-asserted-by":"publisher","first-page":"R21","DOI":"10.1186\/bcr2833","volume":"13","author":"CG Sanchez","year":"2011","unstructured":"Sanchez CG, Ma CX, Crowder RJ, Guintoli T, Phommaly C, Gao F, et al. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res. 2011;13:R21.","journal-title":"Breast Cancer Res"},{"issue":"4","key":"670_CR37","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s12282-017-0812-x","volume":"25","author":"K Araki","year":"2018","unstructured":"Araki K, Miyoshi Y. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K\/Akt\/mTOR in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer. 2017. 2018;25(4):392\u2013401.","journal-title":"Breast Cancer. 2017"},{"key":"670_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13543784.2018.1417384","volume":"27","author":"NM Keegan","year":"2018","unstructured":"Keegan NM, Gleeson JP, Hennessy BT, Morris PG. PI3K inhibition to overcome endocrine resistance in breast cancer. Expert Opin Investig Drugs. 2018;27:1\u201315.","journal-title":"Expert Opin Investig Drugs"},{"key":"670_CR39","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1158\/1078-0432.CCR-05-1029","volume":"12","author":"M Olivier","year":"2006","unstructured":"Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res. 2006;12:1157\u201367.","journal-title":"Clin Cancer Res"},{"key":"670_CR40","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.molonc.2013.12.018","volume":"8","author":"B Gyorffy","year":"2014","unstructured":"Gyorffy B, Bottai G, Lehmann-Che J, Keri G, Orfi L, Iwamoto T, et al. TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers. Mol Oncol. 2014;8:508\u201319.","journal-title":"Mol Oncol"},{"key":"670_CR41","first-page":"2155","volume":"60","author":"EM Berns","year":"2000","unstructured":"Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, et al. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res. 2000;60:2155\u201362.","journal-title":"Cancer Res"},{"key":"670_CR42","first-page":"349","volume":"54","author":"PS Karnik","year":"1994","unstructured":"Karnik PS, Kulkarni S, Liu XP, Budd GT, Bukowski RM. Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res. 1994;54:349\u201353.","journal-title":"Cancer Res"},{"key":"670_CR43","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1093\/jnci\/87.6.446","volume":"87","author":"N Roodi","year":"1995","unstructured":"Roodi N, Bailey LR, Kao WY, Verrier CS, Yee CJ, Dupont WD, et al. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J Natl Cancer Inst. 1995;87:446\u201351.","journal-title":"J Natl Cancer Inst"},{"key":"670_CR44","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov"},{"key":"670_CR45","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","volume":"12","author":"R Jeselsohn","year":"2015","unstructured":"Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R. ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015;12:573\u201383.","journal-title":"Nat Rev Clin Oncol"},{"key":"670_CR46","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1373\/clinchem.2014.221366","volume":"61","author":"JF Huggett","year":"2015","unstructured":"Huggett JF, Cowen S, Foy CA. Considerations for digital PCR as an accurate molecular diagnostic tool. Clin Chem. 2015;61:79\u201388.","journal-title":"Clin Chem"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-018-0670-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13045-018-0670-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-018-0670-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T02:53:00Z","timestamp":1720666380000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-018-0670-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,11]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["670"],"URL":"https:\/\/doi.org\/10.1186\/s13045-018-0670-9","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,11]]},"assertion":[{"value":"26 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was authorized by the French National Agency for Medicines and Health Products Safety and was approved by the Ile de France VIII ethics committee. Participating patients completed the informed consent process.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"I confirm that I have read BioMed Central\u2019s guidance on competing interests and have included a statement indicating that none of the authors have any competing interests concerning this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"124"}}